BACKGROUND: It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). METHODS: AIO-PK0104 was a phase III trial comparing gemcitabine/erlotinib followed by capecitabine with capecitabine/erlotinib followed by gemcitabine in advanced PC. For this post hoc subgroup analysis, biomarker data on the KRAS exon 2 mutation status were correlated with objective response to 1st-line therapy and with overall survival after start of 2nd-line chemotherapy (OSc). RESULTS: KRAS codon 12 was mutated in 121 of 173 (70 %) patients. The KRAS status showed no association with objective response (p = 0.40), but KRAS wildtype patients had an improved OS (HR 1.68, p = 0.005). A trend for a survival benefit was also observed during (non-erlotinib containing) 2nd-line chemotherapy, with a HR of 1.47 (p = 0.10) for the OSc. CONCLUSION: This post hoc analysis of AIO-PK0104 supports the assumption that KRAS is rather a prognostic than a predictive biomarker in PC.
RCT Entities:
BACKGROUND: It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). METHODS: AIO-PK0104 was a phase III trial comparing gemcitabine/erlotinib followed by capecitabine with capecitabine/erlotinib followed by gemcitabine in advanced PC. For this post hoc subgroup analysis, biomarker data on the KRAS exon 2 mutation status were correlated with objective response to 1st-line therapy and with overall survival after start of 2nd-line chemotherapy (OSc). RESULTS:KRAS codon 12 was mutated in 121 of 173 (70 %) patients. The KRAS status showed no association with objective response (p = 0.40), but KRAS wildtype patients had an improved OS (HR 1.68, p = 0.005). A trend for a survival benefit was also observed during (non-erlotinib containing) 2nd-line chemotherapy, with a HR of 1.47 (p = 0.10) for the OSc. CONCLUSION: This post hoc analysis of AIO-PK0104 supports the assumption that KRAS is rather a prognostic than a predictive biomarker in PC.
Authors: Volker Heinemann; Ursula Vehling-Kaiser; Dirk Waldschmidt; Erika Kettner; Angela Märten; Cornelia Winkelmann; Stefan Klein; Georgi Kojouharoff; Thomas C Gauler; Ludwig Fischer von Weikersthal; Michael R Clemens; Michael Geissler; Tim F Greten; Susanna Hegewisch-Becker; Oleg Rubanov; Gerold Baake; Thomas Höhler; Yon D Ko; Andreas Jung; Sascha Neugebauer; Stefan Boeck Journal: Gut Date: 2012-07-07 Impact factor: 23.059
Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316
Authors: Seung Tae Kim; Do Hyoung Lim; Kee-Taek Jang; Taekyu Lim; Jeeyun Lee; Yoon-La Choi; Hye-Lim Jang; Jun Ho Yi; Kyung Kee Baek; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Joon Oh Park Journal: Mol Cancer Ther Date: 2011-08-23 Impact factor: 6.261
Authors: Maria L Amador; Darin Oppenheimer; Sofia Perea; Anirban Maitra; George Cusatis; George Cusati; Christi Iacobuzio-Donahue; Sharyn D Baker; Raheela Ashfaq; Chris Takimoto; Arlene Forastiere; Manuel Hidalgo Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Suzanne Kamel-Reid; Jeremy Squire; Wendy Parulekar; Malcolm J Moore; Ming Sound Tsao Journal: Cancer Date: 2010-09-07 Impact factor: 6.860
Authors: Ching-Wei D Tzeng; Andrey Frolov; Natalya Frolova; Nirag C Jhala; J Harrison Howard; Selwyn M Vickers; Donald J Buchsbaum; Martin J Heslin; J Pablo Arnoletti Journal: Ann Surg Oncol Date: 2007-04-24 Impact factor: 5.344
Authors: Dominik P Modest; Thomas Brodowicz; Sebastian Stintzing; Andreas Jung; Jens Neumann; Ruediger P Laubender; Janja Ocvirk; Galina Kurteva; Zsuzsanna Papai; Regina Knittelfelder; Thomas Kirchner; Volker Heinemann; Christoph C Zielinski Journal: Oncology Date: 2012-08-29 Impact factor: 2.935
Authors: Stephan Kruger; Michael Haas; Steffen Ormanns; Sibylle Bächmann; Jens T Siveke; Thomas Kirchner; Volker Heinemann; Stefan Boeck Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Anna M Czarnecka; Piotr Korzeń; Anna Nowak-Dement; Wojciech Kukwa; Jan Korniluk; Cezary Szczylik Journal: Oncol Lett Date: 2015-12-07 Impact factor: 2.967